The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Novel therapies and clinical trial approaches for Richter’s transformation
Catherine Coombs, MD, UC Irvine Health, Orange, CA, comments on the challenges and potential treatment options for Richter’s transformation (RT) in chronic lymphocytic leukemia (CLL), emphasizing the importance of enrolling patients in clinical trials. She notes that RT is a serious complication and further highlights combinations and novel agents being explored to improve upon the standard of care. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
